Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-28

Study Completion Date

2023-11-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment

NCT03940521

HIV-1-infection

ACTIVE_NOT_RECRUITING

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

NCT03368053

Infection, Human Immunodeficiency Virus HIV Infections

COMPLETED PHASE1

Influenza Vaccination in Patients Living With HIV in the Northern Region

NCT04402684

HIV

COMPLETED

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.

NCT00381212

HIV Seropositivity Acquired Immunodeficiency Syndrome

COMPLETED PHASE1/PHASE2

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

NCT00764946

Human Immunodeficiency Virus

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients meeting the inclusion criteria will be offered to participate to the study.

In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activation and inflammatory markers, during the blood test scheduled for the routine follow-up.

Six months after cART change, an equal volume of blood will be collected for measuring the same immune activation and inflammatory markers

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1-infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients agreeing to participate to the study and to collect their data
* HIV-1 infected subjects
* Patients switching from a stable (at least 6 months) and successful triple cART to a long acting dual cART
* Patients older than 18 yrs and regularly followed in Cannes and Nice hospitals
* Patients with a healthcare card

Exclusion Criteria

* HIV-2 infected subjects
* Patients not being on successful and stable cART
* Patients having being treated during acute HIV-infection
* Patients modifying cART for virological failure
* Subjects modifying their treatment for another combination than from a triple cART to a dual cART
* Patients modifying cART during the 6 months of follow-up
* Patients refusing to participate to the study
* Patients included in an interventional study during the 6 months of follwo-up
* Patient under juridical procedure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No